Skip to main content
main-content

28.11.2018 | Original Article

Amisulpride prevents nausea and vomiting associated with highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled, dose-ranging trial

Zeitschrift:
Supportive Care in Cancer
Autoren:
J. Herrstedt, Y. Summers, K. Jordan, J. von Pawel, A. H. Jakobsen, M. Ewertz, S. Chan, J. D. Naik, M. Karthaus, S. Dubey, R. Davis, G. M. Fox
Wichtige Hinweise
Relevance
This randomised, double-blind trial shows that oral amisulpride, a dopamine D2/D3-receptor antagonist, is safe and superior to placebo at preventing delayed nausea and vomiting associated with highly emetogenic chemotherapy. Amisulpride may therefore have a role in improving management of CINV. Future trials should investigate amisulpride as part of multi-drug CINV prophylaxis.

Abstract

Purpose

Chemotherapy-induced nausea and vomiting (CINV) remain significant clinical problems, especially in the delayed phase (24–120 h after chemotherapy). Amisulpride is a dopamine D2/D3-receptor antagonist previously shown to be an effective intravenous antiemetic. We conducted a randomised, double-blind study to characterise the dose response of oral amisulpride in delayed phase CINV.

Methods

Chemotherapy-naïve patients receiving cisplatin ≥ 70 mg/m2 or an anthracycline-cyclophosphamide regimen for breast cancer received, on day 1, 20 mg amisulpride and 8–16 mg ondansetron intravenously followed, once daily on days 2–4, by 10, 20 or 40 mg oral amisulpride or placebo. A control group receiving standard three-drug prophylaxis was enrolled for assay sensitivity purposes. The primary endpoint was complete response (CR), defined as no emesis or rescue medication use, in the delayed phase.

Results

Three hundred eighteen subjects were evaluable per protocol. CR rate (24–120 h) was 20% with placebo and 46% with 10 mg amisulpride (p = 0.006 after multiplicity adjustment); in the three-drug control group, it was 59%. Emesis, nausea and 0–120-h CR rate were significantly improved with 10 mg amisulpride compared to placebo. Higher doses of amisulpride were not more effective than 10 mg. In patients with acute phase CR, delayed phase CR rate was 44% for placebo, 75% for 10 mg amisulpride (p = 0.022) and 70% for the 3-drug control. No significant differences were seen between groups in safety parameters.

Conclusions

Amisulpride 10 mg orally is safe and superior to placebo at preventing delayed CINV caused by highly emetogenic chemotherapy.

Trial registration

NCT01857232

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Weitere Produktempfehlungen anzeigen
Literatur
Über diesen Artikel
  1. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise